Despite being a wonder drug for COVID-19, Paxlovid suffers deficiencies pertinent to ritonavir associated toxicity and rising resistance to nirmatrelvir, which authors in this work show can be overcome by redesigned viral main protease inhibitors as a mono-therapeutic agent.
- Gan Luo
- Gang Wang
- Wuyuan Lu